EIF5A2: A Potential Drug Target and Biomarker (G56648)
EIF5A2: A Potential Drug Target and Biomarker
Eukaryotic translation initiation factor 5A2 (EIF5A2) is a protein that plays a crucial role in the process of translation of mRNAs from the DNA to protein. It is a key factor in the initiation of the translation process and is involved in the recruitment of several different ribosomes to the start of the mRNA. EIF5A2 has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The discovery of EIF5A2 as a potential drug target comes from a study by the research group of Dr. Qin Liu at the University of California, San Diego. In this study, the researchers found that high levels of EIF5A2 were associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, a type of cancer that affects the pancreas, a gland located behind the stomach that produces enzymes to break down proteins. The researchers also found that blocking the activity of EIF5A2 using a small molecule inhibitor improved the survival of pancreatic ductal adenocarcinoma cells in cell experiments.
EIF5A2 has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In a study by Dr. Li Zhang and his colleagues at the University of California, Davis, the researchers found that mice that were genetically modified to lack EIF5A2 had reduced levels of aggregated beta-amyloid protein, a hallmark of neurodegenerative disease, compared to control mice. The researchers also observed improved cognitive function and reduced ungrateful behavior in the mice that were genetically modified to lack EIF5A2.
EIF5A2 has also been linked to autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. In a study by Dr. Rui Li and his colleagues at the University of Cambridge, the researchers found that mice that were genetically modified to lack EIF5A2 had increased levels of antibodies, a hallmark of autoimmune disease, compared to control mice. The researchers also observed reduced immune function in the mice that were genetically modified to lack EIF5A2.
In addition to its potential as a drug target, EIF5A2 has also been identified as a potential biomarker for several diseases. In a study by Dr. Yinglong Xia and his colleagues at the University of California, San Diego, the researchers found that EIF5A2 was significantly increased in the blood samples of patients with pancreatic ductal adenocarcinoma, a type of cancer that affects the pancreas. The researchers also found that EIF5A2 was associated with poor prognosis in patients with pancreatic ductal adenocarcinoma.
The identification of EIF5A2 as a potential drug target and biomarker is significant because it suggests that targeting this protein may be a promising strategy for treating several diseases. The next step is to conduct further studies to confirm the validity of these findings and to develop a reliable method for delivering small molecules inhibitors to EIF5A2. This research has the potential to improve our understanding of the role of EIF5A2 in the development and progression of disease and to lead to the development of new treatments for a variety of conditions.
Protein Name: Eukaryotic Translation Initiation Factor 5A2
Functions: mRNA-binding protein involved in translation elongation. Has an important function at the level of mRNA turnover, probably acting downstream of decapping. Critical for the efficient synthesis of peptide bonds between consecutive proline residues. Can resolve ribosomal stalling caused by consecutive prolines during translation (By similarity). Involved in actin dynamics and cell cycle progression, mRNA decay and probably in a pathway involved in stress response and maintenance of cell wall integrity. Functions as a regulator of apoptosis. Mediates effects of polyamines on neuronal process extension and survival. May play an important role in brain development and function, and in skeletal muscle stem cell differentiation (By similarity)
The "EIF5A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF5A2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
EIF5AL1 | EIF5B | EIF6 | EIPR1 | ELAC1 | ELAC2 | ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3
